Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer

Meyer, Guy; Marjanovic, Zora; Valcke, Judith; Lorcerie, B.; Gruel, Yves; Solal‐Céligny, Philippe; Maignan, Christine Le; Extra, Jean Marc; Cottu, Paul; Farge, Dominique

doi:10.1001/archinte.162.15.1729

Cited by 748 publications

(210 citation statements)

References 19 publications

Supporting

Mentioning

195

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] According to the results of several randomized clinical trials, [4][5][6][7] international guidelines recommend the use of sub-therapeutic doses of low-molecular-weight heparins (LMWH) for the long-term prevention of recurrent VTE in all cancer patients. [8][9][10] However, in clinical practice many clinicians still administer VKA to their cancer patients, especially to those with limited disease and longer life expectancy.…”

Section: Recurrent Thromboembolism and Major Bleeding During Oral Antmentioning

confidence: 99%

“…[1][2][3][4][5][6] To date, assessment of CMV-specific T-cell immunity has not had a major impact on the clinical management of CMV infection in these patients, as no widely accepted thresholds in the number of CMV-specific T cells providing protection have been established. In the present study, we optimized a simple intracellular cytokine staining (ICS), and investigated whether enumeration of CMV-specific interferon (IFN)γ CD8 + and CD4 + T cells early after transplantation could reliably predict the development of active CMV infection within 100 days after transplantation.…”

Section: Cells Early After Allogeneic Stem Cell Transplantation May Imentioning

confidence: 99%

See 1 more Smart Citation

Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry

Prandoni¹,

Trujillo‐Santos²,

Surico³

et al. 2008

Haematologica

View full text Add to dashboard Cite

Section: Recurrent Thromboembolism and Major Bleeding During Oral Antmentioning

confidence: 99%

Section: Cells Early After Allogeneic Stem Cell Transplantation May Imentioning

confidence: 99%

Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry

Prandoni¹,

Trujillo‐Santos²,

Surico³

et al. 2008

Haematologica

View full text Add to dashboard Cite

“…In these studies, LMWH was compared to vitamin K antagonists (VKA) for the treatment of acute VTE in cancer patients. The pivotal CLOT study showed a significant reduction in VTE recurrence,4 while three other smaller studies showed no difference in efficacy or safety outcomes,30, 31, 32 and the most recent CATCH study33 showed a nonsignificant reduction in VTE recurrence, but a significantly decreased risk of clinically relevant non‐major bleeding (CRNMB) in the LMWH arm. We performed a meta‐analysis of the summary data from these studies using Review Manager (RevMan) [Computer program].…”

Section: Treatment Of Cancer‐associated Thrombosismentioning

confidence: 99%

Managing thrombosis in cancer patients

Wang

García

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Venous thromboembolism is a major complication in cancer patients. The basis for the strong association between cancer and thrombosis remains incompletely understood, and the optimal approaches to both the treatment and the prevention of cancer‐associated thrombosis are evolving. Here we review several important topics related to cancer‐associated thromboembolism, including the pathogenesis, prevention, and management of this disease. Wherever possible, we include evidence from clinical trials, including the results of recently published trials that compared direct oral anticoagulants to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis.

show abstract

“…The use of low molecular weight heparin for secondary prevention of venous thromboembolism in cancer patients may reduce the complication rate [9].…”

Section: Comparison Of Lowmolecular Weight Heparin and Warfarinmentioning

confidence: 99%

Thromboprophylaxis in Cancer Patients-A Review

Kg¹,

Panayappan²,

Komanduri³

et al. 2016

SJAMS

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is a frequent complication of cancer and cancer treatment and is associated with multiple clinical consequences including recurrent venous thromboembolism (VTE), bleeding, and increase in the risk of death. Low molecular weight heparins (LMWH) are often used for long term prophylaxis because of reduced need of coagulation monitoring, few major bleeding episodes and once daily dosing .Low molecular weight heparin have ability to reduce the incidence of VTE and prevent recurrent VT Events in cancer patients. Malignant conditions are frequently associated with a hyper coagulable state, with recurrent thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the coagulation cascade. Heparin and, its pharmacokinetically improved versions, low molecular weight heparins are effective in the prevention and treatment of thromboembolic events in cancer patients. This review article explains the role of the thromboprophylaxis in cancer patients.

show abstract

Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer

Abstract: These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer. Prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients.

Cited by 748 publications

References 19 publications

Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry

Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry

Managing thrombosis in cancer patients

Thromboprophylaxis in Cancer Patients-A Review

Contact Info

Product

Resources

About